Mostrar el registro sencillo del ítem

dc.contributor.authorLacasta, Anna
dc.contributor.authorMonteagudo, Paula L.
dc.contributor.authorJiménez-Marín, Ángeles
dc.contributor.authorAccensi, Francesc
dc.contributor.authorBallester, María
dc.contributor.authorArgilaguet, Jordi
dc.contributor.authorGalindo‑Cardiel, Iván
dc.contributor.authorSegalés, Joaquim
dc.contributor.authorSalas, María L.
dc.contributor.authorDomínguez, Javier
dc.contributor.authorMoreno, Ángela
dc.contributor.authorGarrido, Juan J.
dc.contributor.authorRodríguez, Fernando
dc.date.accessioned2020-03-30T12:17:33Z
dc.date.available2020-03-30T12:17:33Z
dc.date.issued2015
dc.identifier.urihttp://hdl.handle.net/10396/19840
dc.description.abstractAfrican swine fever virus (ASFV) is the causal agent of African swine fever, a hemorrhagic and often lethal porcine disease causing enormous economical losses in affected countries. Endemic for decades in most of the sub-Saharan countries and Sardinia, the risk of ASFV-endemicity in Europe has increased since its last introduction into Europe in 2007. Live attenuated viruses have been demonstrated to induce very efficient protective immune responses, albeit most of the time protection was circumscribed to homologous ASFV challenges. However, their use in the field is still far from a reality, mainly due to safety concerns. In this study we compared the course of the in vivo infection caused by two homologous ASFV strains: the virulent E75 and the cell cultured adapted strain E75CV1, obtained from adapting E75 to grow in the CV1 cell-line. Interestingly, the kinetics of both viruses not only differed on the clinical signs that they caused and in the virus loads found, but also in the immunological pathways activated throughout the infections. Furthermore, E75CV1 confirmed its protective potential against the homologous E75 virus challenge and allowed the demonstration of poor cross-protection against BA71, thus defining it as heterologous. The in vitro specificity of the CD8+ T-cells present at the time of lethal challenge showed a clear activation against the homologous virus (E75) but not against BA71. These findings will be of utility for a better understanding of ASFV pathogenesis and for the rational designing of safe and efficient vaccines against this virus.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherBioMed Centrales_ES
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/es_ES
dc.sourceVeterinary Research 46:135 (2015)es_ES
dc.subjectNasal Swabes_ES
dc.subjectAfrican swine feveres_ES
dc.subjectAfrican swine fever viruses_ES
dc.subjectLethal challengees_ES
dc.subjectLive attenuated vaccinees_ES
dc.titleLive attenuated African swine fever viruses as ideal tools to dissect the mechanisms involved in viral pathogenesis and immune protectiones_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s13567-015-0275-zes_ES
dc.relation.projectIDGobierno de España. AGL201022229es_ES
dc.relation.projectIDGobierno de España. AGL201348998C21Res_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem